Navigation Links
Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
Date:10/7/2009

SALT LAKE CITY, Oct. 7 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced the appointment of Douglas G. Sampson as its new vice president of production and research and development, replacing Ronald Hatch, who has retired.

"We are pleased to add Doug to our management team," said Kelvyn Cullimore Jr., chairman and president of Dynatronics. "His breadth of experience will provide valuable expertise to our manufacturing operation as well as our research and development efforts here at Dynatronics. Doug is an effective leader who has received several awards from consumers for generating quality products."

Mr. Sampson, 55, worked for Philips for 29 years. His positions included executive and management responsibilities in various Philips subsidiaries in Asia and the United States. From 2002 to 2007, he was country manager and managing director of NXP Semiconductor, Philips Semiconductor Thailand, where he was primarily responsible for all aspects of the manufacturing and sales operations of that subsidiary. Most recently, from 2007 to 2008, he served as vice president of outsourced manufacturing for Fairchild Semiconductors in Singapore.

Mr. Sampson earned an executive Master of Business Administration degree from the University of New Mexico, Anderson School of Management. He also holds a Bachelor of Science degree in electronics engineering technology from Brigham Young University, and an Associates degree in electronics engineering technology from Brigham Young University Idaho (formerly Ricks College).

"Ron Hatch has given excellent service to Dynatronics for many years. He will be missed. However, we are confident Doug brings important skill sets to Dynatronics that will enable us to further refine and improve our manufacturing and research and development operations," add
'/>"/>

SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quark Pharmaceuticals Appoints New Chief Medical Officer
2. West Pharmaceutical Services, Inc. Appoints New Director
3. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
4. Curemark Appoints Preeminent Pediatrics Gastroenterologist
5. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. NovaRx Appoints Industry Veteran as President and COO
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ...f-carebloodanalysissystems,announcedtodaythatClint...entatthe21stAnnualPiperJaffrayHealthCareConference...cewillbeheldattheNewYorkPalaceHotelinNewYorkCity. ...resandmarketsportablebloodanalysissystemsforuseina...
(Date:11/25/2009)...ov.25/PRNewswire/--CempraPharmaceuticalsInc.todaya...executiveofficer,willpresentatthePiperJaffray21stA...009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernan...tibioticclinicalprogramsforthetreatmentofdrug-resi...rmaceuticals ,, Foundedin2006,CempraPharmaceut...
(Date:11/25/2009)...ndSYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareIn...novatorandprovideroflessinvasive,miniaturizedcircu...ntofadvancedheartfailure,todayannouncedthatitissch...iperJaffrayHealthCareConferenceat8:00amESTonWednes...wYorkPalaceHotel,December1-2. ,, Alivewebcastof...
Breaking Medicine Technology:Evolution of a contraceptive for sea lamprey 8994 1Evolution of a contraceptive for sea lamprey 8994 2Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 49989 1Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 49989 2Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 49989 3Statement of Dr Elena Rios MD MSPH President and CEO National Hispanic Medical Association 49986 1
...: The Takeda Oncology,Company today reported the P...pany-sponsored Phase I/II study of VELCADE, dexame... in patients with previously untreated multiple,my... data showed that the,combination of four drugs wa...eived no prior therapies and response rates were e...
...aiichi Sankyo,Company, Limited (TSE: 4568), announ...III trial for DU-176b, an investigational oral Fac...tion. DU-176b is being developed,solely by Daiich...ctive Anticoagulation with Factor Xa Next,Generati...l compare DU-176b,with warfarin in preventing stro...
Other Medicine Technology:Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 2Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 3Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation 4
(Date:11/25/2009)...serious behavior problems that can occur in childr...ed with a treatment plan that includes medication ...rents, according to Yale University researchers an... 2009 issue of the Journal of the American Academ...as conducted by the National Institute of Mental H...
(Date:11/25/2009)...found puffs of air on flesh that mimicked parts of... WEDNESDAY, Nov. 25 (HealthDay News) -- People can...eir skin, new research shows. , In fact, sensat...f speech actually helped people decipher sounds be... never been able to show whether we could use tact...
(Date:11/25/2009)... Initiative expands to include ...students, teachers, and healthcare professionals i...asanton, CA (PRWEB) November 25, 2009 -- Ellumina...cial networking solutions that support 21st centu...d today that its Fire and Ice initiative was awa...
(Date:11/25/2009)..., WASHINGTON,Nov.25/PRNewswire-FirstCall/--TheAdvi...twillparticipateinthe21stAnnualPiperJaffrayHealthC...,onDecember2,2009at3:00PM(EST),willbetheCompany,sC...pany,sChiefFinancialOfficer,MichaelT.Kirshbaum.The...website,foundat http://www.advisoryboardcompany.co...
(Date:11/25/2009)..., MT.CLEMENS,Mich.,Nov.25/PRNewswire/--TwomoreH1N1...dSaturday,Dec.5,theMacombCountyHealthDepartmentann...keplaceatFreedomHillCountyParkinSterlingHeights. ,...c.5onewillrunfrom9a.m.to3p.m.Thethimerosol-freever...st,whilesupplieslast.Bothinjectableandnasalsprayim...
Breaking Medicine News(10 mins):Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5Health News:Macomb County Health Department Schedules Two More H1N1 Flu Vaccine Clinics Dec. 3 and 5 2
...people knew the technique, more lives could be sav... If more people had CPR training, the number of in... be dramatically reduced. , That,s the word from t...forming the lifesaving technique. , "There is a tr...
...R, Jan. 18 /PRNewswire-FirstCall/ - QLT Inc. (NASD...s implemented a reduction in its,overall headcount...ely 45%),at its Vancouver headquarters and its U.S...rategic restructuring plan announced on January,16...
...aimed at getting action from Cardinal George and P..., CHICAGO, Jan. 17 Three years ago, health care ...th Cardinal George -- requested he,provide the lea...ng while the abuses, including,exorbitant profits ...
...D, N.J., Jan. 17 Bradley,Pharmaceuticals, Inc. (N...finitive proxy statement with the Securities and E...olders to be held on February 21, 2008 at 9:30,a.m...approve the merger agreement with Nycomed US Inc.,...
... nowhere near ready for general use, experts cauti...- Some patients with heart failure may stand to be...e response. , A study in the Jan. 19 issue of The... subsequent hospitalizations with such a treatment...
...ADELPHIA Researchers at the University of Pennsyl...carrying chemical cargo in nerve cells react diffe...s an important role in Alzheimers disease. , Dyn...ike a speed bump to regulate protein traffic, the ...
Other Medicine News:Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:QLT reduces workforce as first step in its strategic restructure 2Health News:QLT reduces workforce as first step in its strategic restructure 3Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed 2Health News:Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed 3Health News:Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed 4Health News:Immune Therapy May Help Some Heart Failure Patients 2Health News:Immune Therapy May Help Some Heart Failure Patients 3Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: